Level D· Scientific groundwork from lab and animal studiesLaboratory StudyPubMed

3D-printed sacrificial molds for high-resolution, patient-specific hydrogel heart valve engineering.

Rioux Y., Fradette J., Hayward CJ., Séguin V., Bégin-Drolet A., Ruel J.

Laboratory Study on Face & Skin, Systemic / IV, published in Biofabrication (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Biofabrication (2025)
Country
England
Reported sample size
—
Source database
PubMed
PMID
41213244
DOI
10.1088/1758-5090/ae1dd0

Abstract (original English)

The fabrication of anatomically accurate, cellularized heart valve substitutes remains a significant challenge in tissue engineering, particularly for pediatric and patient-specific applications. While three-dimensional (3D) bioprinting enables the creation of complex geometries, it often compromises cell viability and lacks the precision required for small-scale constructs. In this study, we present a high-fidelity, reproducible molding technique using 3D-printed sugar glass molds to engineer custom, alginate-based hydrogel cellularized heart valves. Human adipose-derived stromal cells (ASCs) were used as the cell source due to their accessibility and regenerative potential. This approach overcomes the limitations of conventional molding and bioprinting by enabling the reproduction of intricate anatomical features, including the sinuses of Valsalva, which are critical for physiological hemodynamics. The molding method maintains high cell viability (>90%) at the time of fabrication and the process supports both scalability and automation. Sugar glass molds for valve sizes from 16 to 26 mm inner diameter were printed with 90% of the mold surface within a ±0.3 mm deviation of the reference computer-aided design model. Cellularized valves cultured in a custom perfusion bioreactor retained structural integrity and cell viability over a 14 d period. This biofabrication strategy offe

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Printing, Three-DimensionalHumansTissue EngineeringHydrogelsHeart Valve ProsthesisBioprintingHeart ValvesCell SurvivalTissue ScaffoldsAlginates

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research